Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 4 de 4
Filtrar
1.
J Pediatr ; 191: 259-261.e1, 2017 12.
Artigo em Inglês | MEDLINE | ID: mdl-28967387

RESUMO

Post-hoc analysis of the Randomized Intervention for Children with Vesicoureteral Reflux study suggests that, in concordance with European guidelines, using bacteriologic criterion of ≥10 000 colony forming units/mL of a single organism does not decrease diagnostic specificity of an urinary tract infection in children aged 2 months to 6 years in a properly collected urine if symptoms/fever and pyuria are present. TRIAL REGISTRATION: ClinicalTrials.gov: NCT00405704.


Assuntos
Infecções Urinárias/diagnóstico , Urina/microbiologia , Bacteriúria/diagnóstico , Bacteriúria/etiologia , Criança , Pré-Escolar , Contagem de Colônia Microbiana/normas , Feminino , Febre/etiologia , Humanos , Lactente , Masculino , Piúria/etiologia , Padrões de Referência , Infecções Urinárias/complicações , Infecções Urinárias/microbiologia , Infecções Urinárias/urina
2.
Am J Kidney Dis ; 70(6): 762-769, 2017 Dec.
Artigo em Inglês | MEDLINE | ID: mdl-28801121

RESUMO

BACKGROUND: Elevated uric acid concentration is associated with higher rates of cardiovascular (CV) morbidity and mortality in the general population. It is not known whether hyperuricemia increases the risk for CV death or transplant failure in kidney transplant recipients. STUDY DESIGN: Post hoc cohort analysis of the FAVORIT Study, a randomized controlled trial that examined the effect of homocysteine-lowering vitamins on CV disease in kidney transplantation. SETTING & PARTICIPANTS: Adult recipients of kidney transplants in the United States, Canada, or Brazil participating in the FAVORIT Study, with hyperhomocysteinemia, stable kidney function, and no known history of CV disease. PREDICTOR: Uric acid concentration. OUTCOMES: The primary end point was a composite of CV events. Secondary end points were all-cause mortality and transplant failure. Risk factors included in statistical models were age, sex, race, country, treatment assignment, smoking history, body mass index, presence of diabetes mellitus, history of CV disease, blood pressure, estimated glomerular filtration rate (eGFR), donor type, transplant vintage, lipid concentrations, albumin-creatinine ratio, and uric acid concentration. Cox proportional hazards models were fit to examine the association of uric acid concentration with study end points after risk adjustment. RESULTS: 3,512 of 4,110 FAVORIT participants with baseline uric acid concentrations were studied. Median follow-up was 3.9 (IQR, 3.0-5.3) years. 503 patients had a primary CV event, 401 died, and 287 had transplant failure. In unadjusted analyses, uric acid concentration was significantly related to each outcome. Uric acid concentration was also strongly associated with eGFR. The relationship between uric acid concentration and study end points was no longer significant in fully adjusted multivariable models (P=0.5 for CV events; P=0.09 for death, and P=0.1 for transplant failure). LIMITATIONS: Unknown use of uric acid-lowering agents among study participants. CONCLUSIONS: Following kidney transplantation, uric acid concentrations are not independently associated with CV events, mortality, or transplant failure. The strong association between uric acid concentrations with traditional risk factors and eGFR is a possible explanation.


Assuntos
Doenças Cardiovasculares/mortalidade , Hiper-Homocisteinemia/tratamento farmacológico , Hiperuricemia/epidemiologia , Falência Renal Crônica/epidemiologia , Transplante de Rim , Vitaminas/uso terapêutico , Adulto , Brasil , Canadá , Causas de Morte , Feminino , Taxa de Filtração Glomerular , Humanos , Falência Renal Crônica/cirurgia , Masculino , Pessoa de Meia-Idade , Mortalidade , Análise Multivariada , Modelos de Riscos Proporcionais , Ensaios Clínicos Controlados Aleatórios como Assunto , Fatores de Risco , Estados Unidos
3.
J Pediatr ; 171: 116-21, 2016 Apr.
Artigo em Inglês | MEDLINE | ID: mdl-26794472

RESUMO

OBJECTIVE: To determine which children with urinary tract infection are likely to have pathogens resistant to narrow-spectrum antimicrobials. STUDY DESIGN: Children, 2-71 months of age (n = 769) enrolled in the Randomized Intervention for Children with Vesicoureteral Reflux or Careful Urinary Tract Infection Evaluation studies were included. We used logistic regression models to test the associations between demographic and clinical characteristics and resistance to narrow-spectrum antimicrobials. RESULTS: Of the included patients, 91% were female and 76% had vesicoureteral reflux. The risk of resistance to narrow-spectrum antibiotics in uncircumcised males was approximately 3 times that of females (OR 3.1; 95% CI 1.4-6.7); in children with bladder bowel dysfunction, the risk was 2 times that of children with normal function (OR 2.2; 95% CI 1.2-4.1). Children who had received 1 course of antibiotics during the past 6 months also had higher odds of harboring resistant organisms (OR 1.6; 95% CI 1.1-2.3). Hispanic children had higher odds of harboring pathogens resistant to some narrow-spectrum antimicrobials. CONCLUSIONS: Uncircumcised males, Hispanic children, children with bladder bowel dysfunction, and children who received 1 course of antibiotics in the past 6 months were more likely to have a urinary tract infection caused by pathogens resistant to 1 or more narrow-spectrum antimicrobials.


Assuntos
Anti-Infecciosos/farmacologia , Farmacorresistência Bacteriana , Infecções Urinárias/tratamento farmacológico , Infecções Urinárias/microbiologia , Amoxicilina/farmacologia , Cefalosporinas/farmacologia , Criança , Pré-Escolar , Escherichia coli , Feminino , Humanos , Lactente , Enteropatias/tratamento farmacológico , Enteropatias/epidemiologia , Enteropatias/microbiologia , Masculino , Nitrofurantoína/farmacologia , Razão de Chances , Análise de Regressão , Sulfametoxazol/farmacologia , Trimetoprima/farmacologia , Infecções Urinárias/epidemiologia , Refluxo Vesicoureteral/tratamento farmacológico , Refluxo Vesicoureteral/epidemiologia , Refluxo Vesicoureteral/microbiologia
4.
Am J Kidney Dis ; 53(1): 121-8, 2009 Jan.
Artigo em Inglês | MEDLINE | ID: mdl-19022547

RESUMO

BACKGROUND: Hyperhomocysteinemia may be a modifiable risk factor for the prevention of arteriosclerotic outcomes in patients with chronic kidney disease (CKD). Few clinical trials of homocysteine lowering have been conducted in persons with CKD before reaching end-stage renal disease. Kidney transplant recipients are considered individuals with CKD. OBJECTIVES: To describe the baseline characteristics of renal transplant recipients enrolled in a clinical trial of homocysteine lowering with a standard multivitamin containing high doses of folic acid and vitamins B(6) and B(12) aimed at reducing arteriosclerotic outcomes. Factors considered were level of kidney function, total homocysteine concentration, and prevalence of diabetes and previous cardiovascular disease (CVD). STUDY DESIGN: Cross-sectional survey within a randomized controlled trial cohort. SETTING & PARTICIPANTS: Participants were recruited from kidney transplant clinics in the United States, Canada, and Brazil. Eligible participants had increased levels of homocysteine (> or =12.0 micromol/L in men and > or =11.0 micromol/L in women) and kidney function measured by means of Cockroft-Gault estimated creatinine clearance of 30 mL/min or greater. RESULTS: Of 4,110 randomly assigned participants, 38.9% had diabetes and 19.5% had previous CVD. Mean total homocysteine concentration was 17.1 +/- 6.3 (SD) micromol/L, whereas mean creatinine clearance was 66.4 +/- 23.2 mL/min. Approximately 90% of the trial cohort had an estimated glomerular filtration rate consistent with stages 2 to 3 CKD (i.e., 30 to 89 mL/min). LIMITATIONS: Analysis is based on cross-sectional data from a randomized controlled trial, self-report of comorbid illnesses, and level of kidney function was estimated. CONCLUSIONS: A large population of stable renal transplant recipients who are at high risk of the development of CVD (both de novo and recurrent) has been recruited into the Folic Acid for Vascular Outcome Reduction in Transplantation Trial and are likely to experience a sufficient number of events to address the primary hypothesis of the trial.


Assuntos
Doenças Cardiovasculares/prevenção & controle , Ácido Fólico/uso terapêutico , Nefropatias/cirurgia , Transplante de Rim , Complexo Vitamínico B/uso terapêutico , Adulto , Brasil , Canadá , Doenças Cardiovasculares/sangue , Doenças Cardiovasculares/etiologia , Doença Crônica , Estudos de Coortes , Creatinina/sangue , Estudos Transversais , Relação Dose-Resposta a Droga , Feminino , Taxa de Filtração Glomerular/fisiologia , Homocisteína/sangue , Humanos , Rim/fisiopatologia , Nefropatias/sangue , Nefropatias/complicações , Masculino , Pessoa de Meia-Idade , Fatores de Risco , Resultado do Tratamento , Estados Unidos
SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA